Ipsen.com - SEO Checker

Sign up for free! PDF Export
Overview of the SEO Check
Meta information
80% 
Page quality
87% 
Page structure
75% 
Link structure
41% 
Server
91% 
External factors
100% 
SEO Score
Response time
0.29 s
File size
171.50 kB
Words
1392
Media files
45
Number of links
138 internal / 7 external

Task list of SEO Improvements

Meta specifications

Title
(Critically important)
Ipsen Global - A Biopharmaceutical Company | Innovation for Patient Care
The page title should be shorter than 580 pixels. It is 664 pixels long. Optimize title
There are no duplicate words in the title
Meta description
(Critically important)
Ipsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.
The length of the meta description is perfect. (835 pixels out of 1000 max pixel length)
Crawlability
(Critically important)
There are no problems in accessing the website.
Canonical URL
(Important)
https://www.ipsen.com/
There is a valid canonical link specified.
Language
(Somewhat important)
Language detected in text: en
Language defined in HTML: en-us
Server location: United States of America
The following language is defined by HTML: en-us
Alternate/Hreflang Links
(Somewhat important)
The specified alternate links have no errors.
Other meta tags
(Somewhat important)
There is no rel next meta tag on this page.
There is no rel prev meta tag on this page.
Domain
(Somewhat important)
The domain is no subdomain.
The domain length is good.
The domain does not contain non-latin characters.
Page URL
(Somewhat important)
No parameters were found in the URL.
No session ID was found in the URL.
The URL does not have too many subdirectories.
Charset encoding
(Somewhat important)
The charset encoding (UTF-8) is set correctly.
Doctype
(Nice to have)
The doctype HTML 5 is set correctly.
The doctype is placed at first in the HTML code.
Favicon
(Nice to have)
The favicon is linked correctly.

Meta tags

NameValue
viewportwidth=device-width, initial-scale=1
robotsindex, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1
descriptionIpsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.
google-site-verificationjgzhVZarP1499LBpCYuY60W5QzkLY9-_hcm5_6ZQ0G4
generatorWPML ver:4.6.9 stt:1,4;
msapplication-TileImagehttps://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/04/19135239/favicon.png
article:modified_time2024-10-29T15:52:10+00:00
langen-us
twitter:cardsummary_large_image
twitter:site@ipsengroup
og:localeen_US
og:typewebsite
og:titleIpsen Global - A Biopharmaceutical Company | Innovation for Patient Care
og:descriptionIpsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.
og:urlhttps://www.ipsen.com/
og:site_nameGlobal
X-UA-CompatibleIE=edge
charsetUTF-8

Test up to 1.000 webpages of ipsen.com with our free plan!

Try For Free
No trial. It's just free!

Page quality

Content
(Critically important)
The average number of words per sentence of 28.21 words is high.
This page contains 1392 words. That's ok.
30.6% of the text are stop words.
Keywords used in the page title are also used in the page content. That's good!
The page contains a listing, which indicates a good text layout.
30 paragraphs were found on this page.
The text content is perfect.
No placeholders texts or images were found.
There are no duplicates on the site.
Frames
(Critically important)
This page does not use a frameset.
Mobile optimization
(Somewhat important)
A viewport "width=device-width, initial-scale=1" is provided.
At least one Apple touch icon is specified.
Bold and strong tags
(Somewhat important)
The usage of strong and bold tags is perfect. We recommend the use of up to 28 tags for this page.
Image SEO
(Somewhat important)
7 images have no alt attribute. The content of alt attributes is used by search engines.
Social Networks
(Nice to have)
There are only a few social sharing widgets on the page. Make your website popular in social networks with social sharing widgets.
Additional markup
(Nice to have)
No additional page markup was found.
HTTPS
(Somewhat important)
This website uses HTTPS to protect privacy and integrity of the exchanged data.
All included files are also transferred via HTTPS.

Media list

URLAlt attributeTitle
data:[...] Base64Home
data:[...] Base64arrow_downarrow_down
data:[...] Base64Featured ImageFeatured Image
data:[...] Base64arrow_downarrow_down
data:[...] Base64arrow_downarrow_down
data:[...] Base64arrow_downarrow_down
data:[...] Base64GlobalGlobal
data:[...] Base64arrow_downarrow_down
data:[...] Base64arrow_downarrow_down
data:[...] Base64arrow_downarrow_down
data:[...] Base64arrow_downarrow_down
data:[...] Base64Hero BannerHero Banner
data:[...] Base64Hero BannerHero Banner
data:[...] Base64Hero BannerHero Banner
data:[...] Base64Hero BannerHero Banner
data:[...] Base64WHAT WE DOWHAT WE DO
data:[...] Base64Author ImageAuthor Image
data:[...] Base64No alt attribute providedIpsen delivers strong sales momentum in the first nine months of 2024 and increases its...
data:[...] Base64No alt attribute providedIpsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare...
data:[...] Base64No alt attribute providedIpsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary...
data:[...] Base64No alt attribute providedIpsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat)...
data:[...] Base64No alt attribute providedIpsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary...
data:[...] Base64No alt attribute providedOur 2023 Integrated Annual Report is live!
data:[...] Base64Image infoImage info
data:[...] Base64Image infoImage info
data:[...] Base64Image infoImage info
data:[...] Base64Image infoImage info
data:[...] Base64Image infoImage info
data:[...] Base64SUSTAINABILITYSUSTAINABILITY
data:[...] Base64Science-First Collaborations: Ipsen’s Blueprint to External InnovationScience-First Collaborations: Ipsen’s Blueprint to External Innovation
data:[...] Base64Ipsen is now a great place to work in 28 countries: A New Milestone in our culture journeyIpsen is now a great place to work in 28 countries: A New Milestone in our culture journey
data:[...] Base64Building a Sustainable Future: Ipsen’s Journey with the United Nations Global Compact Building a Sustainable Future: Ipsen’s Journey with the United Nations Global Compact 
data:[...] Base64Financial results for the first nine months of 2024Financial results for the first nine months of 2024
data:[...] Base64Excellence in action: Ipsen is first pharma company to receive two Gold Shingo PrizesExcellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
data:[...] Base64Sustainability in the Supply Chain: Ipsen’s First Supplier Sustainability Day Sustainability in the Supply Chain: Ipsen’s First Supplier Sustainability Day 
data:[...] Base64Looking after a loved one with Progressive Familial Intrahepatic Cholestasis: Francesca’s StoryLooking after a loved one with Progressive Familial Intrahepatic Cholestasis: Francesca’s Story
data:[...] Base64Ipsen Achieves Its Record-High Score in 2024 S&P Global CSA, Setting New Company Benchmark Ipsen Achieves Its Record-High Score in 2024 S&P Global CSA, Setting New Company Benchmark 
data:[...] Base64Ipsen’s Commitment to Zero Emissions: A Step Towards a Sustainable Future Ipsen’s Commitment to Zero Emissions: A Step Towards a Sustainable Future 
data:[...] Base64Partnering for Progress: The Importance of Collaboration in Primary Biliary Cholangitis (PBC) Awareness  Partnering for Progress: The Importance of Collaboration in Primary Biliary Cholangitis (PBC) Awareness  
data:[...] Base64No alt attribute provided
data:[...] Base64LinkedInLinkedIn
data:[...] Base64TwitterTwitter
data:[...] Base64FacebookFacebook
data:[...] Base64InstagramInstagram
data:[...] Base64YoutubeYoutube

Page structure

H1 heading
(Critically important)
There is no H1 heading specified.
Headings
(Important)
The structure of headings is missing one or more levels. Do not skip heading levels.
Some headings do not have any content.

Heading structure

Heading levelContent
H2 Focus. Together. For patients and society.
H2 Ipsen Way of Being
H2 Partnering for success
H2 Guided by patient outcomes
H2 Empty heading
H2 The latest highlights from Ipsen
H2 How Ipsen helps
H2 Careers at Ipsen
H2 Discover trending stories
H3 Putting patients at the heart of our work
H3 Empty heading
Some internal link anchor texts are too long.
Some anchor texts are used more than once.
12 links don't have an anchor text.
There are 1 links with a trivial anchor text.
The number of internal links is ok.
All internal links are not using dynamic parameters.
There are 7 external links on this page.

Found links on this page

LinkAttributesAnchor text
https://www.ipsen.com/Subdomain IMG-ALT Home
/press-release/Subdomain Press Releases
/media-statements/Subdomain Media Statements
/media-library/Subdomain Media Library
/general/our-2023-integrated-a...Subdomain Our 2023 Integrated Annual Report is live!
https://www.ipsen.com/investors/Subdomain Investors
/investors/financial-results/Subdomain Financial Results
/investors/reports-and-accounts/Subdomain Annual Reports and Accounts
/investors/corporate-news/Subdomain Corporate News
/investors/financial-calendar/Subdomain Financial Calendar
/investors/investor-events/Subdomain Investor Events
/investors/shareholders-inform...Subdomain Shareholder Information
https://tools.euroland.com/inv...External Subdomain Share-Price Data
/investors/regulated-information/Subdomain Regulated Information
/contact-us/key-contacts/Subdomain Key Contacts
https://www.ipsen.com/partnering/Subdomain Partnering
https://www.ipsen.com/careers/Subdomain Careers
/careers/working-at-ipsen/Subdomain Working at Ipsen
/careers/our-culture/Subdomain Culture
https://www.ipsen.com/Subdomain English  EN
https://www.ipsen.com/fr/Subdomain Français  FR
https://www.ipsen.com/Subdomain EnglishEN
https://www.ipsen.com/fr/Subdomain FrançaisFR
https://www.ipsen.com/Subdomain Global
https://www.ipsen.com/Subdomain EN
https://www.ipsen.com/frSubdomain FR
/annualreportSubdomain Annual Report
/annualreportSubdomain Text duplicate EN
/annualreport/frSubdomain Text duplicate FR
https://www.ipsen.com/us/New window Subdomain United States
https://www.ipsen.com/brazil/New window Subdomain Brazil
https://www.ipsen.com/canada/New window Subdomain Canada EN
https://www.ipsen.com/canada/fr/New window Subdomain Canada FR
https://www.ipsen.com/aus/New window Subdomain Australia
https://www.ipsen.com/cn/New window Subdomain China
https://www.ipsen.com/singapore/New window Subdomain Singapore
https://www.ipsen.com/korea/New window Subdomain South Korea
https://www.ipsen.com/japan/New window Subdomain Japan
https://www.ipsen.com/be/New window Subdomain Belgium
https://www.ipsen.com/ukraine/New window Subdomain Ukraine
https://www.ipsen.com/uk-ireland/New window Subdomain UK
https://www.ipsen.com/germany/New window Subdomain Germany
https://www.ipsen.com/france/New window Subdomain France
https://www.ipsennordic.com/New window External Subdomain Nordics
https://www.ipsen.com/greece/New window Subdomain Greece
https://www.ipsen.com/it/New window Subdomain Italy
/netherlands/New window Subdomain Netherlands
https://www.ipsen.com/spain/New window Subdomain Spain
https://www.ipsen.com/poland/New window Subdomain Poland
https://www.ipsen.com/russia/New window Subdomain Russia
https://www.ipsen.com/czc/New window Subdomain Czech Republic
/switzerland/New window Subdomain Switzerland
https://www.ipsen.com/Subdomain Text duplicate Home
https://www.ipsen.com/company/Subdomain Company
/company/leadership-team/Subdomain Leadership
/company/history/Subdomain History
/company/foundation-ipsen/Subdomain Fondation Ipsen
https://www.ipsen.com/oncology/Subdomain Oncology
/rare-diseases/Subdomain Rare Disease
/neuroscience/Subdomain Neuroscience
/our-products/Subdomain Products
/research-and-development/Subdomain R&D
https://www.ipsen.com/pipeline/Subdomain Pipeline
/clinical-trials/Subdomain Clinical Trials
/lay-summaries/Subdomain Lay Summaries
/sustainability/Subdomain Sustainability
/sustainability/environment/Subdomain Environment
/sustainability/patients/Subdomain Patients
/sustainability/people/Subdomain People
/sustainability/governance/Subdomain Governance
/sustainability/our-standards/Subdomain Our Standards
https://www.ipsen.com/patients/Subdomain Text duplicate Patients
/patients/together-for-oncology/Subdomain Together for Oncology
/patients/together-for-rare-di...Subdomain Together for Rare Disease
/patients/together-for-neurosc...Subdomain Together for Neuroscience
/patients/collaborate-with-us/Subdomain Collaborate with us
https://www.ipsen.com/stories/Subdomain Stories
https://www.ipsen.com/company/Subdomain Learn about our strategy
https://www.ipsen.com/careers/Subdomain Trivial anchor text
Read more
https://www.ipsen.com/partnering/Subdomain Find out more
/research-and-development/Subdomain Learn more
/research-and-development/Subdomain Text duplicate Learn more
/press-releases/ipsen-delivers...Subdomain No Text
/press-releases/ipsen-delivers...Subdomain No Text
/press-releases/ipsen-delivers...Subdomain Financial – 23 October 2024 Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its…
/press-releases/ipsens-kayfand...Subdomain No Text
/press-releases/ipsens-kayfand...Subdomain No Text
/press-releases/ipsens-kayfand...Subdomain Rare Diseases – 23 September 2024 Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare…
/press-releases/ipsens-iqirvo-...Subdomain No Text
/press-releases/ipsens-iqirvo-...Subdomain No Text
/press-releases/ipsens-iqirvo-...Subdomain Rare Diseases – 20 September 2024 Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary…
/press-releases/ipsen-receives...Subdomain No Text
/press-releases/ipsen-receives...Subdomain No Text
/press-releases/ipsen-receives...Subdomain Rare Diseases – 26 July 2024 Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat)…
/press-releases/ipsens-iqirvo-...Subdomain No Text
/press-releases/ipsens-iqirvo-...Subdomain No Text
/press-releases/ipsens-iqirvo-...Subdomain Rare Diseases – 10 June 2024 Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary…
/general/our-2023-integrated-a...Subdomain No Text
/general/our-2023-integrated-a...Subdomain No Text
/general/our-2023-integrated-a...Subdomain General – 31 May 2024 Our 2023 Integrated Annual Report is live!
https://www.ipsen.com/oncology/Oncology Ipsen has been working in oncology since 1986, and now has a portfolio that includes treatments for neuroendocrine tumor (NETs), and cancers of the ...
/rare-diseases/Rare Disease Ninety-four percent of rare medical conditions still have no treatment. We are committed to finding treatments for extremely rare bone diseases ...
/neuroscience/Neuroscience Ipsen draws on 30 years of expertise in toxins and neuroscience research to support children and adults suffering from debilitating and degenera...
https://www.ipsen.com/patients/Subdomain Text duplicate Learn more
/responsibility/Subdomain Text duplicate Learn more
https://www.ipsen.com/careers/Subdomain Explore careers at Ipsen
/partnering/science-first-coll...Subdomain IMG-ALT Science-First Collaborations: Ipsen’s Blueprint to External Innovation
A-TITLE Science-First Collaborations: Ipsen’s Blueprint to External Innovation
/partnering/science-first-coll...Subdomain Text duplicate Science-First Collaborations: Ipsen’s Blueprint to External Innovation
A-TITLE Science-First Collaborations: Ipsen’s Blueprint to External Innovation
/culture/ipsen-is-now-a-great-...Subdomain IMG-ALT Ipsen is now a great place to work in 28 countries: A New Milestone in our culture journey
A-TITLE Ipsen is now a great place to work in 28 countries: A New Milestone in our culture journey
/culture/ipsen-is-now-a-great-...Subdomain Text duplicate Ipsen is now a great place to work in 28 countries: A New Milestone in our culture journey
A-TITLE Ipsen is now a great place to work in 28 countries: A New Milestone in our culture journey
/sustainability/building-a-sus...Subdomain IMG-ALT Building a Sustainable Future: Ipsen’s Journey with the United Nations Global Compact
A-TITLE Building a Sustainable Future: Ipsen’s Journey with the United Nations Global Compact
/sustainability/building-a-sus...Subdomain Text duplicate Building a Sustainable Future: Ipsen’s Journey with the United Nations Global Compact
A-TITLE Building a Sustainable Future: Ipsen’s Journey with the United Nations Global Compact
/general/financial-results-for...Subdomain IMG-ALT Financial results for the first nine months of 2024
A-TITLE Financial results for the first nine months of 2024
/general/financial-results-for...Subdomain Text duplicate Financial results for the first nine months of 2024
A-TITLE Financial results for the first nine months of 2024
/pressrelease/corporate-pressr...Subdomain IMG-ALT Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
A-TITLE Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
/pressrelease/corporate-pressr...Subdomain Text duplicate Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
A-TITLE Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
/sustainability/sustainability...Subdomain IMG-ALT Sustainability in the Supply Chain: Ipsen’s First Supplier Sustainability Day
A-TITLE Sustainability in the Supply Chain: Ipsen’s First Supplier Sustainability Day
/sustainability/sustainability...Subdomain Text duplicate Sustainability in the Supply Chain: Ipsen’s First Supplier Sustainability Day
A-TITLE Sustainability in the Supply Chain: Ipsen’s First Supplier Sustainability Day
/rare-diseases/looking-after-a...Subdomain IMG-ALT Looking after a loved one with Progressive Familial Intrahepatic Cholestasis: Francesca’s Story
A-TITLE Looking after a loved one with Progressive Familial Intrahepatic Cholestasis: Francesca’s Story
/rare-diseases/looking-after-a...Subdomain Text duplicate Looking after a loved one with Progressive Familial Intrahepatic Cholestasis: Francesca’s Story
A-TITLE Looking after a loved one with Progressive Familial Intrahepatic Cholestasis: Francesca’s Story
/sustainability/environment/ip...Subdomain IMG-ALT Ipsen Achieves Its Record-High Score in 2024 S&P Global CSA, Setting New Company Benchmark
A-TITLE Ipsen Achieves Its Record-High Score in 2024 S&P Global CSA, Setting New Company Benchmark
/sustainability/environment/ip...Subdomain Text duplicate Ipsen Achieves Its Record-High Score in 2024 S&P Global CSA, Setting New Company Benchmark
A-TITLE Ipsen Achieves Its Record-High Score in 2024 S&P Global CSA, Setting New Company Benchmark
/sustainability/ipsens-commitm...Subdomain IMG-ALT Ipsen’s Commitment to Zero Emissions: A Step Towards a Sustainable Future
A-TITLE Ipsen’s Commitment to Zero Emissions: A Step Towards a Sustainable Future
/sustainability/ipsens-commitm...Subdomain Text duplicate Ipsen’s Commitment to Zero Emissions: A Step Towards a Sustainable Future
A-TITLE Ipsen’s Commitment to Zero Emissions: A Step Towards a Sustainable Future
/rare-diseases/partnering-for-...Subdomain IMG-ALT Partnering for Progress: The Importance of Collaboration in Primary Biliary Cholangitis (PBC) Awareness 
A-TITLE Partnering for Progress: The Importance of Collaboration in Primary Biliary Cholangitis (PBC) Awareness 
/rare-diseases/partnering-for-...Subdomain Text duplicate Partnering for Progress: The Importance of Collaboration in Primary Biliary Cholangitis (PBC) Awareness 
A-TITLE Partnering for Progress: The Importance of Collaboration in Primary Biliary Cholangitis (PBC) Awareness 
https://www.ipsen.com/stories/Subdomain View all stories
A-TITLE View all stories
/press-release/Subdomain Media
https://www.ipsen.com/investors/Subdomain Text duplicate Investors
https://www.ipsen.com/partnering/Subdomain Text duplicate Partnering
https://www.ipsen.com/careers/Subdomain Text duplicate Careers
https://www.ipsen.com/company/Subdomain Text duplicate Company
/sustainability/Subdomain Text duplicate Sustainability
https://www.ipsen.com/patients/Subdomain Text duplicate Patients
https://www.ipsen.com/stories/Subdomain Text duplicate Stories
/annualreport/New window Subdomain Text duplicate Annual Report
https://www.ipsen.com/contact-us/Subdomain Contact us
https://www.linkedin.com/compa...New window External Subdomain IMG-ALT LinkedIn
https://twitter.com/ipsengroupNew window External IMG-ALT Twitter
https://www.facebook.com/Ipsen...New window External Subdomain IMG-ALT Facebook
https://www.instagram.com/ipse...New window External Subdomain IMG-ALT Instagram
https://www.youtube.com/IpsenB...New window External Subdomain IMG-ALT Youtube
/terms-and-conditions/Subdomain Terms and Conditions
/cookie-policy/Subdomain Cookie Policy
/global-privacy-policy/Subdomain Global Privacy Policy

Server configuration

HTTP redirects
(Critically important)
This page redirects to "https://www.ipsen.com/"
HTTP header
(Important)
The web server version is sent within the HTTP header.
No X-Powered HTTP header is sent.
This page uses GZip for compressed data transmission.
Performance
(Somewhat important)
A Content Delivery Network like Google Hosted Libraries can save bandwidth for the JQuery files.
A Content Delivery Network like Bootstrap CDN can save bandwidth for Bootstrap front-end component library.
The page response time is excellent with 0.29 seconds.
The file size of the HTML document is fine (172 kB).

HTTP Response Header

NameValue
content-typetext/html; charset=UTF-8
content-length28277
cache-controlmax-age=0
content-encodinggzip
dateSun, 03 Nov 2024 12:06:08 GMT
expiresSun, 03 Nov 2024 12:06:08 GMT
last-modifiedSun, 03 Nov 2024 11:38:13 GMT
serverApache/2.4.62 () OpenSSL/1.0.2k-fips
set-cookie166 Characters
varyAccept-Encoding
x-cacheMiss from cloudfront
via1.1 a23fc047c59f0902384fa94644607c00.cloudfront.net (CloudFront)
x-amz-cf-popFRA56-P3
x-amz-cf-id7sU3KDpj0zVvzohXGG9y21fndBhKII4zhRg1UBwtDKtKr99KRezZ1w==
statuscode200
http_versionHTTP/2

External factors

This page is referenced by wikipedia.
This website has excellent links from other websites.
This page has backlinks from 2,708 referring domains.
This page has 463,737 backlinks.
This page has backlinks from 2,076 different ip addresses.

Links from Wikipedia

You can find more links using Wikipedia search

Robots.txt

User-agent: *
Disallow: /wp-admin/
Allow: /wp-admin/admin-ajax.php
Disallow: /wp-includes/
Allow: /wp-includes/js/
Allow: /wp-includes/images/
Disallow: /trackback/
Disallow: /wp-login.php
Disallow: /wp-register.php
Disallow: /?s=*

Sitemap: https://www.ipsen.com/sitemap_index.xml

Similar sites

Search preview

www.ipsen.com
Ipsen Global - A Biopharmaceutical Company | Innovation for Patient...
Ipsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.

Most important keywords

Following keywords were found. You can check the keyword optimization of this page for each keyword.

KeywordResultRecheck
Ipsen81%Check
Ipsen global71%Check
Global63%Check
innovation60%Check
Company60%Check
global biopharmaceutical company60%Check
Biopharmaceutical Company59%Check
Ipsen Way58%Check
Patients56%Check
2024 Global52%Check
Show more keywords and terms

Test up to 1.000 webpages of ipsen.com with our free plan!

Try For Free
No trial. It's just free!

Cookie Policy

We use cookies to make our site work and also for analytics and advertising purposes. You can enable or disable optional cookies as desired. See the following links for more information.

Contact | Privacy

We need these so the site can function properly

So we can better understand how visitors use our website

So we can serve you tailored ads and promotions